Drug Profile
Artemether topical - EpiPharm
Alternative Names: EPI SK14Latest Information Update: 20 Oct 2021
Price :
$50
*
At a glance
- Originator EpiPharm
- Class Anthelmintics; Antifungals; Antimalarials; Antineoplastics; Antiprotozoals; Artemisinins; Fluorenes; Skin disorder therapies; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Carrier protein inhibitors; Mitochondrial protein inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Seborrhoeic keratosis
Most Recent Events
- 05 Sep 2017 Artemether topical is still in phase II trial for seborrhoeic keratosis in Switzerland (EpiPharm pipeline, September 2017)
- 01 Jul 2015 EpiPharm completes a phase II trial in Seborrhoeic keratosis in Switzerland (ISRCTN12424904)
- 20 Feb 2015 Phase-II clinical trials in Seborrhoeic keratosis in Switzerland (Topical)